Compare AU
Compare RBTZ vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Robotics and Artificial Intelligence ETF (RBTZ) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
RBTZ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 416 | 63 |
Median incremental investment | $793.50 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,500.00 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Key Summary
RBTZ | DRUG | |
|---|---|---|
Strategy | RBTZ.AX was created on 2018-09-12 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. RBTZ.AX aims to track the performance of an index (before fees and expenses) that includes global companies involved in the production or use of robotics and artificial intelligence (A.l.) products and services. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | NVIDIA CORP (12.43 %) ABB LTD (9.74 %) INTUITIVE SURGICAL INC (8.84 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (57.27 %) Information Technology (27.35 %) Health Care (9.40 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (47.60 %) Japan (30.01 %) Switzerland (11.60 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.57 % | 0.57 % |
Key Summary
RBTZ | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Indxx Global Robotics & Artificial Intelligence Thematic Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.57 % |
Price | $15.00 | $8.12 |
Size | $278.291 million | $182.401 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.81 % | 1.90 % |
Market | ASX | ASX |
First listed date | 14/09/2018 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
RBTZ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 416 | 63 |
Median incremental investment | $793.50 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,500.00 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
RBTZ | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
RBTZ | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |